Literature DB >> 11927384

Evidence for a sustained increase in clonal beta-cell basal intracellular Ca2+ levels after incubation in the presence of newly diagnosed Type-1 diabetic patient sera. Possible role in serum-induced inhibition of insulin secretion.

S J Conroy1, I Green, G Dixon, P M Byrne, J Nolan, Y H A Abdel-Wahab, N McClenaghan, P R Flatt, P Newsholme.   

Abstract

We have previously reported that newly diagnosed Type-1 diabetic patient sera potently suppressed insulin secretion from a clonal rat pancreatic beta-cell line (BRIN BD11) but did not alter cell viability. Here, we report that apoptosis in BRIN BD11 cells incubated in various sera types (fetal calf serum (FCS), normal human serum and Type-1 diabetic patient) was virtually undetectable. Although low levels of necrosis were detected, these were not significantly different between cells incubated in sera from different sources. ATP levels were reduced by approximately 30% while nitrite production increased twofold from BRIN BD11 cells incubated for 24 h in the presence of Type-1 diabetic patient sera compared with normal human sera. Additionally, ATP levels were reduced by approximately 40% and DNA fragmentation increased by more than 20-fold in BRIN BD11 cells incubated in FCS in the presence of a pro-inflammatory cytokine cocktail (interleukin-1beta, tumour necrosis factor-alpha and interferon-gamma), compared with cells incubated in the absence of cytokines. Nitric oxide production from BRIN BD11 cells was markedly increased (up to 10-fold) irrespective of sera type when the cytokine cocktail was included in the incubation medium. Type-1 diabetic patient sera significantly (P<0.001) raised basal levels of intracellular free Ca(2+ )concentration ([Ca(2+)](i)) in BRIN BD11 cells after a 24-h incubation. The alteration in [Ca(2+)](i) concentration was complement dependent, as removal of the early complement components C1q and C3 resulted in a significant reduction (P<0.01) of sera-induced [Ca(2+)](i )changes. We propose that the mechanism of Type-1 diabetic patient sera-induced inhibition of insulin secretion from clonal beta-cells may involve complement-stimulated elevation of [Ca(2+)](i) which attenuates the nutrient-induced insulin secretory process possibly by desensitizing the cell to further changes in Ca(2+).

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11927384     DOI: 10.1677/joe.0.1730053

Source DB:  PubMed          Journal:  J Endocrinol        ISSN: 0022-0795            Impact factor:   4.286


  5 in total

Review 1.  The central role of calcium in the effects of cytokines on beta-cell function: implications for type 1 and type 2 diabetes.

Authors:  James W Ramadan; Stephen R Steiner; Christina M O'Neill; Craig S Nunemaker
Journal:  Cell Calcium       Date:  2011-09-23       Impact factor: 6.817

2.  Protective Role of Complement C3 Against Cytokine-Mediated β-Cell Apoptosis.

Authors:  Reinaldo S Dos Santos; Laura Marroqui; Fabio A Grieco; Lorella Marselli; Mara Suleiman; Stefan R Henz; Piero Marchetti; Rasmus Wernersson; Decio L Eizirik
Journal:  Endocrinology       Date:  2017-08-01       Impact factor: 4.736

3.  Evidence that low-grade systemic inflammation can induce islet dysfunction as measured by impaired calcium handling.

Authors:  Stacey B Dula; Mladen Jecmenica; Runpei Wu; Pooya Jahanshahi; Gretchen M Verrilli; Jeffrey D Carter; Kenneth L Brayman; Craig S Nunemaker
Journal:  Cell Calcium       Date:  2010-08-25       Impact factor: 6.817

Review 4.  The role of the complement system in metabolic organs and metabolic diseases.

Authors:  Julia Phieler; Ruben Garcia-Martin; John D Lambris; Triantafyllos Chavakis
Journal:  Semin Immunol       Date:  2013-05-17       Impact factor: 11.130

5.  Overexpression of the malate-aspartate NADH shuttle member Aralar1 in the clonal beta-cell line BRIN-BD11 enhances amino-acid-stimulated insulin secretion and cell metabolism.

Authors:  Katrin Bender; Pierre Maechler; Neville H McClenaghan; Peter R Flatt; Philip Newsholme
Journal:  Clin Sci (Lond)       Date:  2009-09-01       Impact factor: 6.124

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.